# Radha Pharmaceuticals Inc.

Canonical: https://abierto.us/vendors/radha-pharmaceuticals-inc-c1s5sq88ky67

- UEI: C1S5SQ88KY67
- CAGE: 8PNH3
- Location: Hauppauge, NY
- Awards in window: 18 (49 transactions), $0 obligated, February 8, 2024 to September 3, 2026

## Awarding agencies

- Department of Veterans Affairs: 13 awards, $0
- Defense Logistics Agency: 5 awards, $0

## Industries

- 325412 Pharmaceutical Preparation Manufacturing: $0

## Competition

- Full and Open Competition: 18 awards

## Solicitations won

- Bupropion HCL ER (SPE2D2-21-R-0105), $23,278,524. https://abierto.us/opportunities/spe2d221r0105
- Naproxen Tablets 8-1-2026 - 7-31-2027 (36E79726R0011), $12,991,005. https://abierto.us/opportunities/36e79726r0011
- Celecoxib Capsules (SPE2D2-25-R-0021), $15,771,598. https://abierto.us/opportunities/spe2d225r0021
- Hydralazine HCL Tablets Effective 04/08/2026 to 04/07/2027 (36E79725R0060), $7,450,453. https://abierto.us/opportunities/36e79725r0060
- Fexofenadine Tablets (SPE2D2-24-R-0010), $10,819,189. https://abierto.us/opportunities/spe2d224r0010
- Bupropion HCL 12HR SA Tablets Effective 05/16/2026 - 05/15/2027 (36E79725R0065), $8,284,706. https://abierto.us/opportunities/36e79725r0065
- Pharm Manuf/Distr Div - FSA (SPE2D2-25-R-0009), $7,507,756. https://abierto.us/opportunities/spe2d225r0009
- Buspirone Award (36E79725R0024), $18,126,659. https://abierto.us/opportunities/36e79725r0024
- Ranolazine SA Tablets - Radha - 11/20/25 - 11/19/26 (36E79725R0036), $11,667,090. https://abierto.us/opportunities/36e79725r0036
- CELECOXIB (SPE2D2-20-R-0075). https://abierto.us/opportunities/spe2d220r0075
- Carbidopa/Levodopa SA Tablet (36E79725R0008), $10,813,880. https://abierto.us/opportunities/36e79725r0008

## Largest awards

- 36E79721D0004: $0, Nac Pharmaceuticals. Exercising 3RD Option Year for Hydralazine Tablets with No Price Changes. https://www.usaspending.gov/award/CONT_IDV_36E79721D0004_3600/
- 36E79721D0022: $0, Nac Pharmaceuticals. Update to Cost Recovery Fee (Crf) and Submission of Quarterly Sales Reports 36E79721D0022, Radha Pharmaceuticals INC. for Bupropion HCL SA Tablets.. https://www.usaspending.gov/award/CONT_IDV_36E79721D0022_3600/
- 36E79721D0026: $0, Nac Pharmaceuticals. Supplemental Change to Update to Cost Recovery Fee (Crf) and Submission of Quarterly Sales Reports for 36E79721D0026 for Naproxen Tablets. https://www.usaspending.gov/award/CONT_IDV_36E79721D0026_3600/
- 36E79722D0035: $0, Nac Pharmaceuticals. CRF Submittal and Sales Reporting Changes. https://www.usaspending.gov/award/CONT_IDV_36E79722D0035_3600/
- 36E79723D0004: $0, Nac Pharmaceuticals. This Modification Is Issued to Exercise the 1ST Option Year for Clopidogrel Bisulfate Tablets.. https://www.usaspending.gov/award/CONT_IDV_36E79723D0004_3600/
- 36E79723D0025: $0, Nac Pharmaceuticals. Update to Cost Recovery Fee (Crf) and Submission of Quarterly Sales Reports. https://www.usaspending.gov/award/CONT_IDV_36E79723D0025_3600/
- 36E79723D0029: $0, Nac Pharmaceuticals. Change in CRF Payment Submittal and Sales Reporting. https://www.usaspending.gov/award/CONT_IDV_36E79723D0029_3600/
- 36E79725D0026: $0, Nac Pharmaceuticals. 2 Line Items: Carbidopa 25mg/Levodopa 100MG Tab,sa Carbidopa 50mg/Levodopa 200MG Tab,sa Awarded for a Base Year of 5/23/2025 to 5/22/2026 Plus 4 ON-YEAR Option Periods.. https://www.usaspending.gov/award/CONT_IDV_36E79725D0026_3600/
- 36E79725D0043: $0, Nac Pharmaceuticals. New Award for Ranolazine Sustained Action Tablets with Radha Pharmaceuticals INC. Base Year Ordering Period Is November 20, 2025 to November 19, 2026 with Four ONE-YEAR Options.. https://www.usaspending.gov/award/CONT_IDV_36E79725D0043_3600/
- 36E79725D0044: $0, Nac Pharmaceuticals. New Award for Buspirone HCL Tablets with Radha. Ordering Period Is Oct 3, 2025 to Oct 2, 2026 with Four ONE-YEAR Options. https://www.usaspending.gov/award/CONT_IDV_36E79725D0044_3600/
- 36E79726D0012: $0, Nac Pharmaceuticals. New Award for Bupropion HCL 12HR SA Tablets with Radha Pharmaceuticals INC. Base Year Ordering Period Is May 16, 2026 to May 15, 2027 with Four ONE-YEAR Options.. https://www.usaspending.gov/award/CONT_IDV_36E79726D0012_3600/
- 36E79726D0013: $0, Nac Pharmaceuticals. New Award for Hydralazine HCL Tablets with Radha Pharmaceuticals with Four ONE-YEAR Options. https://www.usaspending.gov/award/CONT_IDV_36E79726D0013_3600/
- 36E79726D0029: $0, Nac Pharmaceuticals. New Award for Naproxen Tablets with Radha Pharmaceuticals, INC. Period of Performance Is 8/1/2026-7/31/2027.. https://www.usaspending.gov/award/CONT_IDV_36E79726D0029_3600/
- SPE2D221D0130: $0, DLA Troop Support. 4610071871!manufacture/Distributor BR-PH. https://www.usaspending.gov/award/CONT_IDV_SPE2D221D0130_9700/
- SPE2D223D0002: $0, DLA Troop Support. 4610095053!manufacture/Distributor BR-PH. https://www.usaspending.gov/award/CONT_IDV_SPE2D223D0002_9700/
- SPE2D225D0005: $0, DLA Troop Support. 4610117962!pharm Manuf/Distr Div - FSA. https://www.usaspending.gov/award/CONT_IDV_SPE2D225D0005_9700/
- SPE2D226D0003: $0, DLA Troop Support. 4610127744!. https://www.usaspending.gov/award/CONT_IDV_SPE2D226D0003_9700/
- SPE2D226D0010: $0, DLA Troop Support. 4610133531!. https://www.usaspending.gov/award/CONT_IDV_SPE2D226D0010_9700/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/radha-pharmaceuticals-inc-c1s5sq88ky67.